Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Signed study-specific consent form prior to registration.~* Pathologically confirmed malignant melanoma.~* Measurable melanoma lesion deemed to require radiation by treating physicians for purposes of local control or palliation. The lesion may be the primary melanoma, a nodal metastasis, or a distant metastasis. Recurrent lesions are allowed.~* Lesion has to be measurable clinically or radiographically in 2 dimensions.~* Karnofsky Performance Scale (KPS) \> 70.~* Laboratory values~  * White blood cells (WBC) \> 3000/mm3~ * Absolute granulocyte count \> 1,500~ * Platelets \> 100,000/mm3~ * Total bilirubin \< 2.0 x institutional upper limit of normal~ * AST or ALT (aminotransferase/alanine aminotransferase) \< 2.5 x institutional upper limit of normal~ * Serum calcium \< 1.3 x institutional upper limit of normal~ * Serum creatinine \< 1.5 mg/dL or Creatinine clearance \> 50 cc/min,calculated as follows: CCr = 0.85 x (140-age) x (weight in kg) 72 x serum creatinine in mg/dL~Exclusion criteria:~* Systemic therapy for malignant melanoma within one month preceding trial enrollment.~* Prior irradiation to the planned field.~* Concomitant chemotherapy (in addition to cisplatin) or biologic therapy is allowed.~* Significant infection or other co-existent medical condition which would prevent the use of full dose chemotherapy.~* Pre-existing sensory neuropathy (CTC 3.0 ≥ Grade II)~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All participants (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).